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ABSTRACT 
 
With the advent of combinatorial chemistry and high throughput screening of drug 
molecules, poorly water soluble molecules have been entering the development stage 
as new drug candidates. The poor aqueous solubility of these molecules is one of the 
limiting factors for them to succeed as a new drug product. This had led to converting 
these drugs in most cases are crystalline to amorphous solid dispersion with use of 
amorphous polymers to improve the solubility. 
Although amorphous solid dispersion of a poorly water drug can improve the 
solubility, careful selection of polymer is a necessity in order to stabilize the high 
energy nature of the amorphous solid dispersion. Miscibility of a drug and a polymer 
is important. With specific interaction between the drug and the polymer, the 
dispersion can remain miscible much longer. Another factor that needs to be 
considered when formulating an amorphous solid dispersion is the amount of drug that 
is incorporated into the polymer. Over saturating the polymer with the drug can cause 
instability of the dispersion and crystallization may occur which will lead to reduced 
solubility. 
 
In this work, effects of processing method, polymer selection and the drug 
concentrations for the preparation of amorphous solid dispersion as well as prediction 
of drug-polymer miscibility have been studied. Hot melt extrusion (HME), rotary 
evaporation (Rot) and spray drying (SD) processing methods used in the study with 
  
 
Eudragit E 100 (EPO), HPMCAS LF and PVPVA 64 polymers. Drug concentration 
was another factor that was explored.  
 
The objective of this dissertation were: (1) to prepare amorphous solid dispersion of 
nifedipine with polymers (2) to characterize the solid dispersions (3) to determine the 
factors which contributes to successful amorphous solid dispersion (4) to evaluate 
prediction methods used to study drug and polymer miscibility and solubility (5) to 
use a thermodynamic prediction model to determine solubility of nifedipine at room 
temperature. 
In the first manuscript, amorphous solid dispersions of nifedipine and polymers were 
prepared. Physical and chemical characterizations of the solid dispersions indicated 
solid dispersions prepared with EPO polymer were unstable although intrinsic 
dissolution rates (IDR) of those samples had higher rates than those prepared with 
HPMCAS LF or PVPVA 64 polymers. The instability was explained by the lack of 
specific hydrogen bond interaction while the high IDR was explained by the low glass 
transition temperature (Tg) of the polymer. With lower Tg, molecular mobility would 
be higher and therefore the drug could dissolve at a faster rate. ANOVA analysis of 
factorial design showed all factors (process, polymer and drug concentration) affected 
the IDR. Further optimization of experiments may be necessary to determine the 
dominant factor for improving IDR. 
In the second manuscript, we have calculated three different ways to calculate the 
Flory-Huggins interaction parameter, χ. Although using melting point depression 
approach and solubility parameter of a drug and a polymer are common to estimate the 
  
 
miscibility of the two, there were assumptions that needed to be addressed. We have 
modified the melting point depression approach by calculating a better estimate of 
volume fractions needed to calculate the interaction parameter. 
In the third manuscript, we have taken a recently published thermodynamic prediction 
model, which can estimate the stable drug concentration that can be incorporated into 
an amorphous solid dispersion at room temperature, to predict the solubility of 
nifedipine with EPO, HPMCAS LF and PVPVA 64 polymers in amorphous solid 
dispersions prepared by HME, Rot and SD processes. The predictions showed less 
stable nifedipine concentration could be incorporated into HME processed solid 
dispersions than samples prepared by Rot or SD processes. Overall, nifedipine-
PVPVA 64 solid dispersion prepared by SD method was predicted to incorporate 
nifedipine concentration up to 30 % w/w. 
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PREFACE 
This dissertation has been prepared in the manuscript format as outlined in the 
formatting guideline provided by the Graduate School of University of Rhode Island. 
The entire dissertations were divided into three manuscript sections. 
 
Manuscript 1: Evaluation of Processing Method, Polymer Selection and Drug Load 
on Amorphous Solid Dispersion of Nifedipine 
Manuscript 2: Testing the use of “heat of fusion” in calculations of interaction 
parameter (χ) in Flory-Huggins and its comparison with the use of melting point 
depression and solubility parameters  
Manuscript 3: A Study of Stability Prediction of the Nifedipine Solid Dispersions 
Prepared with Hot Melt Extrusion, Spray Drying and Rotary Evaporation 
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Abstract 
Purpose: To evaluate the characteristics of amorphous solid dispersions of nifedipine 
processed  with hot melt extrusion (HME), rotary evaporation(ROT) and spray 
drying(SD) at 5,10,20 and 40% w/w drug loadings, to determine the differences 
involved in the final products. 
Methods: Amorphous solid dispersion of nifedipine with Eudragit E 100 (Polymethyl 
methacrylate), HPMCAS LF and PVPVA 64 were prepared via hot melt extrusion, 
rotary evaporation and spray drying processes.  The solid dispersions were analyzed 
with DSC, FT-IR, PXRD and the intrinsic dissolution rates (IDR) were determined. 
Results:  NIF-EPO samples prepared by HME and SD showed the highest IDR. 
However, analytical characterizations of the same samples show unstable amorphous 
solid dispersion. To keep the molecular mobility of the amorphous solid dispersion to 
a minimum to inhibit recrystallization, a system such as NIF-PVPVA 64  may be give 
a better stable amorphous solid dispersions. 
 
Keywords  
Amorphous, Process Methods, Solid Dispersion, Intrinsic Dissolution Rate, Polymer 
 
 
Introduction 
Amorphous solid dispersions are one of the forms used in the pharmaceutical industry 
to manipulate poorly water soluble drug molecules; to improve their solubility in 
aqueous media and to achieve higher level of bioavailability. In an amorphous solid 
dispersion, the hydrophobic drug is dispersed in an amorphous hydrophilic polymer 
carrier by different means. The action of the polymer is twofold: to stabilize the 
 3 
 
amorphous state of the drug and to improve the dissolution of the drug (1-5, 11). In 
some cases, the use of polymer have shown to prevent precipitation of the drug from a 
supersaturated solution created as the result of higher solubility of the amorphous form 
compared to the crystalline one. (6, 7)  
In the literature, the effects of processing methods on the final product properties are 
rarely mentioned; for example, etravirine was processed by two different methods; via 
film casting, and solvent evaporation and the effects of methodologies used on the 
final solid dispersions were compared (7).  
Weuts et al., studied the changes occurred in the melt and the spray dried powder and 
they found that melting process provided a higher miscibility and longer stability 
whereas the spray drying method was not sufficient to produce stable products (8). 
Patterson et al. mentioned the differences in the drug properties obtained by quench 
cooling and ball milling methods. However, the effects of each method used, were 
different on each of the drugs used for testing (9).  
  
Amorphous solid dispersion can be prepared by several methods such as physical 
manipulation (i.e. milling) (9, 10), precipitation from solvents (11), melting (9, 12, 13) 
and solvent removal (11,13). The two most commonly used amorphous processing 
methods in the pharmaceutical industry are melting (fusion) and solvent removal. The 
fusion method employs high temperatures to melt both the drug and the polymer 
together; disperse the drug molecules throughout the polymer matrix and quench cool 
the mixture by either extruding the mixture or by placing the molten mixture in an ice 
bath or liquid nitrogen. The solvent removal method can produce an amorphous solid 
 4 
 
dispersion by dissolving a poorly water soluble drug and a polymer in the same 
organic solvent. In most cases a type of alcohol is used as a solvent and then the 
solvent is removed by evaporation, lyophilization, vacuum drying or supercritical 
condition respectively.  
 
Comparison of the effects of the processing methods, including the effects of different 
polymers used on the final products has been studied very little. We believe that the 
methods that we have selected will produce products of different characteristics. The 
reasoning behind this can be, for example, to investigate the differences in the rate of 
solvent evaporation for rotary evaporation compared to spray drying. In spray drying 
the solvent can evaporate from the droplets of drug-polymer combination in 
“milliseconds” which can lead to a successful solid dispersion (13). The typical 
evaporation capacity of the rotary evaporation and spray-drying differs since rotary 
dryer can have evaporation rate of 30-80 kg H2O/ h∙m
3
 compared to spray dryer which 
has 1-3 kg H2O/ h∙ m
3
 (17).  
 
Janssens et al. compared spray dried amorphous solid dispersion of itraconazole to 
film casted samples (11). The crystallization temperature of itraconazole reported for 
the two processing methods showed that the onset of crystallization for the film casted 
samples were lower which meant that the solid dispersions prepared by this process 
gave less stable products by influencing the crystallization behavior of the drug in the 
polymer. 
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In this study, amorphous solid dispersions of nifedipine (NIF), which is a calcium 
channel blocker, used for the treatment of high blood pressure and to control angina, 
with three different polymers, Eudragit E 100 [Poly(butyl methacrylate-co-(2-
demethylaminoeethyl) methacrylate-co-methyl methacrylate)], HPMCAS LF 
(hydroxypropylmethylcellulose acetate succinate), PVPVA 64 (polyvinyl pyrrolidone 
vinyl acetate) coprecipites. They were  prepared by using hot melt extrusion (HME), 
spray drying (SD) and rotary evaporation (Rot). The processed formulations were 
analyzed for physical, thermal and chemical properties by using modulated differential 
scanning calorimetry (MDSC), Fourier transform infrared spectroscopy (FT-IR), 
powder X-ray diffraction (PXRD). The intrinsic dissolution rates were also measured 
to relate properties obtained with the  solubility of the final product. 
 
MATERIALS AND METHODS 
 
MATERIALS 
The API (Active pharmaceutical ingredient) used was, nifedipine (NIF) purchased 
from RIA International (East Hanover, NJ). Eudragit E-100 (EPO) polymer which was 
kindly provided by Evonik (Parsippany, NJ), HPMCAS LF from Shin-Etsu Chemical 
Co., Ltd (Biddle Sawyer Corp, New York, NY) and PVPVA  64 was purchased from 
BASF (Florham Park, NJ). 
Methylene chloride was used as the solvent in both spray drying and rotary 
evaporation processes as received. For processing NIF with HPMCAS LF, methanol 
was used because HPMCAS LF does not dissolve in methylene chloride. Both 
solvents were purchased from Sigma-Aldrich Co. (St. Louis, MO).  
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Fig. 1-1 shows the chemical structures of the drug and the polymers and Table I lists 
the physical-chemical properties of the drug and the polymers.  
 
 
 
METHODS  
 
Hot Melt Extrusion (HME) 
 
Physical mixtures of NIF and EPO were prepared using a mortar and pestle with drug 
loadings of 5, 10, 20 and 40 % w/w. The mixture was then extruded using Haake 
Minilab micro compounder (Thermo Scientific, Waltham, MA). The extruded material 
was ground and sized through a # 40 sieve. A diagram of a hot melt extruder is shown 
in Appendix 1, Fig IA-1 
In this machine, the physical mixture went into the extruder through the funnel on the 
left hand side and softened with the temperature applied and extrudes out from the 
flush hole. The extrusion screw speed was set to 50 RPM throughout the experiments 
and no shear force was additionally applied to the mixture. 
 
 
Rotary Evaporation (Rot) 
 
 The same physical mixtures prepared for HME were used for rotary evaporation. 
Physical mixtures of 5-10 grams were dissolved in 50-100 mL of methylene chloride, 
for EPO and PVPVA 64 respectively. The solvents were removed by using a rotary 
evaporator apparatus (Büchi Rotavapor from Büchi (New Castle, DE). The rotary 
evaporator was set to approximately 30 RPM for all experiments conducted. The 
 7 
 
samples were collected by removing the foamy film formed on the walls of the flask 
with a metal spatula and ground by using a mortar and pestle. The particles were sized 
through a # 40 sieve.  
 
Spray Drying (SD) 
 
A Mini Spray Dryer B-290 (Büchi, New Castle, DE) attached to Inert Loop B-295 
cooling block was used in the spray drying experiment to manufacture amorphous 
solid dispersion of nifedipine prepared with three different polymers respectively. A 
solution of NIF and polymer in methylene chloride (methanol in the case when 
HPMCAS LF) was used as the polymer matrix having drug loads ranging from 5-40% 
w/w. A solid content of 3 to 5% w/w solid content were used in order to adjust the 
workability of the sample. 
In Appendix I, the geometry of the spray dryer is shown in Fig. IA-2.  
In this spray dryer, the solution is atomized from (1) while nitrogen is continuously 
supplied from (2). The atomized droplets are dried in the heated chamber (3) and are 
collected in the collection vessel through cyclone in (4). Smaller particles are removed 
from the nitrogen flow by a filter located in (5) and the gas flows out to (6) to be 
condensed to collect the solvent.  
In our experiments, the pump speed was set to 24%, inlet temperature to 7   C, and 
aspirator to 90% on the control panel. The two-fluid nozzle was used to allow 
compressed air to disperse the pumped liquid into fine droplets. An electronic heater 
was used to heat the nitrogen gas which would dry the droplets to evaporate the 
solvent. The droplets would continue to dry in the spray cylinder and, a cyclone 
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created, separated the particles into the collection container or into the outer filter. 
Aspirator located at the end of the spray dryer was used to generate the nitrogen flow 
and to collect the used solvent into the cooling block. 
Materials collected were transferred into an amber colored vial and were kept in 
desiccators until further analysis. 
 
 
Methods Used for Analytical Tests 
 
Modulated differential scanning calorimetry (MDSC) 
 
NIF-polymer samples were thermally analyzed with a MDSC instrument Q2000 (TA 
Instruments, New Castle, DE).  Samples to be scanned were weighed (6- 8 mg) and 
placed in to aluminum pans with lids. Heating was controlled throughout the 
measurement and the samples were heated from room temperature up to 20- 30°C 
above the melting point of the pure drug at a rate of 5°C/ minute unless noted 
otherwise. The samples were kept at the highest temperature for two minutes and then 
cooled down to -50°C at -50°C/minute cooling rate. The samples were kept at the 
lowest temperature for a maximum of 2 minutes and then heated up to 20-30 °C above 
the melting point of the drug.  
 
Fourier transform-infrared spectroscopy (FT-IR) 
FT-IR used was Nicolet 6700 FT-IR spectrometer (Thermo Scientific, Waltham, MA) 
to collect infrared spectra. The FT-IR was equipped with Smart Orbit ATR 
(Attenuated Total Reflection) objective lens with a diamond crystal in reflection 
mode. OMNIC software program was used to analyze the data.  
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Powder X-ray diffraction (PXRD) 
PXRD was performed by using X-ray diffraction obtained with Bruker D8 XRD. The 
samples were analyzed using Cu, K α radiation to determine the crystalline or 
amorphous phases of the drugs. The X-Ray pattern was collected in the angular range 
of   < 2θ < 40° in the step scan mode (step width 0.02°, scan rate  °/ per minute). 
 
Intrinsic dissolution rate determination (IDR) 
 
Dissolution studies using solid dispersions samples obtained, which contained 5, 10, 
20 and 40% w/w NIF and the three polymers respectively, were prepared by HME, 
Rot and SD, were conducted to determine the intrinsic dissolution rates. USP II 
apparatus with an amber vessel was used for the study. Fig. IA-3 in Appendix I shows 
the setup of an intrinsic dissolution vessel with a die, containing a drug compact 
exposing a single surface to the dissolution media at the bottom. Approximately 200 
mg of sample was weighed and compressed in a disk with a press using 2000 lbs. 
force with 5 second dwelling time. Dissolution media used in the experiments were 
500 mL of 0.1 N hydrochloric acid with pH of 1.2 for NIF-EPO samples. Phosphate 
buffer with pH6.8 was used for all other samples. Temperature used was 37  C. IDR 
was determined using the initial linear profile of the dissolution plot. The 3x3x4 
factorial design of experiments were analyzed with a general linear model of ANOVA 
to determine the effects of processing methods, polymer choice and drug 
concentration on IDR. 
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RESULTS 
 
 
Products Obtained with Hot Melt Extrusion (HME) 
 
In HME, we observed significant changes at the –NH stretch and the C=O of the ester 
groups with the wavelength changing at 3318 cm
-1
 and at1676 cm
-1
 peaks  which 
agrees with previous reporting (23) that indicate hydrogen bond interaction with NIF-
HPMCAS LF and NIF-PVPVA 64 samples occurred, see Figs. 1-.2 and 3. No 
significant interaction was present with NIF-EPO samples. The peak at 3318 cm
-1
 
which is associated with the –NH moiety, shifts to a lower wave number and the peak 
broadening and shift to a higher wave number of the C=O have been linked to 
hydrogen bonding interaction between nifedipine and polymer solid dispersions (24, 
25). 
According to the DSC thermograms, HME process creates amorphous solid 
dispersions up to 20 % drug concentrations for all polymers and up to 40 % drug 
concentration for NIF-PVPVA 64 solid dispersions. With NIF-EPO and NIF-
HPMCAS LF samples, at 40 % drug concentration, melting endotherms were 
observed, see Figs. 1.4 and 1.5. Although all the samples prepared by HME process 
had one Tg which are shown in Table   , suggesting a one-phase amorphous solid 
dispersion, a melting endotherm seen at  6   C which was preceded with a 
recrystallization peak of  the NIF-EPO sample indicated thermal instability; 
crystallization of NIF was not apparent in the XRD data, Fig. 1- 6. There was also a 
melting endotherm that was observed at  6   C of the NIF-HPMCAS LF sample at 40 
% drug concentration, which was not preceded by a recrystallization peak. This may 
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suggest that there were small nifedipine clusters in the solid dispersion that did not 
convert to amorphous form that had melted while the sample was heated in the DSC 
instrument, see Fig. 1- 7. They were too small to be detected by the XRD.  
The findings from the XRD can suggest the possible limitation of high-angle x-ray 
diffraction. The presence of the melting endotherm may be the result of applied heat 
resulted in an unstable amorphous solid dispersion by the DSC, which caused 
recrystallization of the drug. 
When the dissolution rates of the samples obtained with HME were investigated 
(Table III ), it is seen that the increasing dissolution rates are obtained with increasing 
drug concentrations with EPO and HPMCAS LF. This is an expected finding. 
However, with PVPVA 64 polymer, dissolution rates are not following the same path. 
The reason may be that the high solubility of PVPVA 64 in water compared to EPO 
and HPMCAS LF. When the polymer engulfing the nifedipine molecules in a solid 
dispersion dissolves immediately, it exposes the drug molecules to the dissolution 
medium resulting high concentration of drug, which may be the reason of rapid 
crystallization and precipitation resulting lower intrinsic dissolution rate. 
 
 
Products obtained with Rotary evaporation (Rot) 
 
Rotary evaporation also caused hydrogen bonding of nifedipine with; HPMAS and 
PVPVA 64, see Figs. 1-8 and 1-9. However, the DSC data, with PVPVA 64, Fig 1- 0, 
demonstrates the presence of two glass transition temperatures. The first appears at 
  .0   C and the second at  2 . 7  C. Although the X-ray diffractions showed 
amorphous product at all drug concentrations, shown in Fig. 1-11, the DSC data may 
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indicate the presence of two amorphous phases, one being the drug-rich, the other 
being the polymer rich regions since the change in the glass transition temperatures 
have shifted from a lower temperature to a higher one that is closer to the glass 
transition temperature of the polymer. Occurrence of two glass transition temperature 
regions could be the result of phase separation of the amorphous solid dispersions. 
This was suggested by Rumondor et al. (16).  
 
 n the   C spectrogram, 20 %   F-E O sample showed a melting endotherm at 
 47.07  C which suggests that there are crystalline nifedipine present in the solid 
dispersion, see Fig. 1- 12. In 40 % NIF-EPO sample, also a similar melting endotherm 
is present, at   0.    C, Fig. 1-13. The melting endotherm is accompanied with a 
recrystallization peak which suggests that it is a combination of crystalline nifedipine 
and unstable amorphous nifedipine that reverted to the crystalline form.  
 
The XRD results for the NIF-EPO solid dispersions confirm the presence of 
crystalline nifedipine at 40 % drug concentration Fig. 1- 14. Sample prepared with 
HPMCAS LF polymer e hibited a melting endotherm at 40 % nifedipine 
concentration at  63.3   C, Fig. 1- 15.  This melting endotherm indicates the presence 
of undissolved nifedipine that had melted during the DSC scan. This crystalline 
nifedipine was also detected in the XRD spectrogram in Fig 1-16.   
The intrinsic dissolution rates calculated , increase up to 20 % NIF-EPO samples and 
decrease about 50 times for 40 % drug concentration Table I.III.   The presence of 
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both undissolved and unstable amorphous nifedipine could be the cause for the 
reduced dissolution rate. 
For NIF-HPMCAS LF samples, there is a linear relationship between the drug 
concentration and the IDR. With increase in the drug concentration, the IDR will also 
increase even at 40 % drug concentration which contains crystalline nifedipine. The 
reason for not seeing the reduction in the IDR at 40 % drug concentration, maybe the 
result of HPMCAS LF’s ability to inhibit precipitation of amorphous drug in 
dissolution media. 
 
For PVPVA polymer, dissolution rates appear to be random and not consistent with 
increasing drug concentration. As explained earlier, the two glass transition regions 
seen in Fig. 1- 10, the possible phase separated nifedipine  may be the cause for 
inconsistent trend.  
 
 
Products Obtained with Spray Drying (SD) 
 
Spray dried samples showed no interaction between nifedipine and EPO but showed 
strong interaction between nifedipine and PVPVA 64 at 2937 cm
-1
 and 1698 cm-
1
. 
Similar interactions were seen given in Fig 1-8 and1-  .  amples prepared with E O 
were amorphous up to 20 % drug concentration, according to the   C thermogram 
which showed melting endotherm at   0.67  C accompanied by a recrystallization 
peak, Fig. 1- 17. This recrystallization was not apparent in the XRD diffractograms 
shown in Fig. 1- 18.  
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NIF-HPMCAS LF sample containing 40 % nifedipine also e hibited a melting 
endotherm at    .04  C shown in Fig 1-19. This melting was not preceded with 
recrystallization of the amorphous drug. In the XRD spectrograms,shown in Fig 1-20, 
all of the samples demonstrated  amorphous characteristics.  
 
Spray drying process creates an amorphous solid dispersion where the drug is trapped 
in the polymer matrix instantaneously, but the dispersion created by this manner may 
be unstable. XRD measurement which does not utilize heating may not show any 
crystallinity, whereas DSC  which supplies energy in the form of heat to the sample 
during measurement may indicate the instability of the  amorphous nifedipine solid 
dispersion by showing a melting peak. Explanation for the melting endotherm that 
appears at a higher nifedipine concentration may be demonstrating instability.  
 
Intrinsic dissolution rates of the samples prepared with this method are given in Table 
III.  
Increasing EPO and HPMCAS LF increase the IDR. However PVPVA 64 at 20 and 
40 % drug concentration demonstrates lower rates than the lower drug concentrations. 
This could be due to the highly water-soluble nature of the PVPVA polymer that the 
supersaturation that is caused with the release of high concentration of nifedipine may 
result in a reversion of amorphous nifedipine to crystalline state. Since PVPVA 64 
does not have the same inhibition property as HPMCAS LF, the released nifedipine 
may have crystallized in the dissolution media. 
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Over all , spray drying process can incorporate 20% of drug in the solid dispersion 
regardless of the type, molecular weight and structure of the polymers used. 
 
Intrinsic Dissolution Rates Comparison 
 
In Fig. 1- 21, the IDR of all the samples prepared by HME, Rot and SD using three 
different polymers, EPO, HPMCAS LF and PVPVA 64 at four different drug 
concentrations are shown. From this plot, it can be seen that NIF-EPO sample that was 
spray dried with 40 % drug concentration has the highest IDR. To attain a better idea 
of factors that affected the IDR, we have looked into other properties of the prepared 
solid dispersion. 
 
Investigation of TableI-   gives us information about the ΔHfus which is indicating that 
the drug was not reverted to the amorphous form.   n HME method, the value of  ΔHfus 
is 2.4 J/g for NIF-EPO sample at 20 % drug concentration and 20.2 J/g at 40 % drug 
concentration. For NIF-HPMCAS LF sample, at 40 %, there was a melting endotherm 
with ΔHfus measuring 5.2 J/g.  
For Rot, in E O, ΔHfus is 2.8 J/g for the NIF-EPO sample at 20 % drug concentration 
and 21.1 J/g at 40 % drug concentration. NIF-HPMCAS LF e hibited ΔHfus of 12.4 
J/g at 40 % drug concentration.  
For SD process both NIF-EPO and NIF-HPMCAS LF samples at 40 % drug 
concentrations were presented with, ΔHfus as 20.3 and 8.6 J/g respectively. These 
findings suggest that Rot process is the least efficient method to convert crystalline 
drug into amorphous solid dispersions where the crystalline drug is still present at 20 
% concentration. On the other hand, SD is the most efficient process where all 
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polymer converted nifedipine into amorphous solid dispersion up to 20 % drug 
concentration. 
The ANOVA analysis of the IDR of the amorphous solid dispersions in order to 
determine the factors that may influence the intrinsic dissolution rate showed that 
interaction of all three factors (i.e. processing, polymer type and drug concentration) 
which will change the IDR of amorphous nifedipine solid dispersions with changes in 
any one factor or factors combined. 
For example, investigating the interaction plots shown in Fig. 1- 22, we can conclude 
that if we want to choose the best processing method with the highest drug 
concentration, we should choose SD method. On the other hand, if we want to choose 
the optimum process and polymer combination, we should select SD with EPO. EPO 
at 40 % drug concentration yields the highest IDR. Since all three factors affect the 
IDR significantly, we cannot conclude that any one of the factor is the dominant one, 
in terms of yielding a high intrinsic dissolution rate. Since process conditions were not 
optimized for preparing the amorphous solid dispersions, optimization of each process 
and using design of experiments may provide the answer to this question. 
 
Discussions 
The results from the IDR experiments show that NIF-EPO samples prepared by HME 
or SD have higher dissolution rate. The slightly acidic nature of nifedipine results in 
the higher intrinsic dissolution rate in an acidic aqueous medium as shown with 
amorphous solid dispersions prepared with EPO at all three processing methods. 
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Overall, the higher drug loading resulted in faster dissolution rates across all three 
polymers and processing methods.  
 
The MDSC measurements, resulted with a melting endotherm appearing at the drug 
loading of 20%,w/w,  as it is seen in NIF-EPO systems Fig. 1-4,  indicated 
metastability even though its IDR is high. There is high risk in such solid dispersions, 
because the metastable amorphous NIF, can revert back to the crystalline form either 
during dissolution or while the samples sit on the shelf. Therefore, NIF-PVPVA 64 
samples should be used as more suitable combinations processed by any of the 
methods tested in this study, even if their IDR are lower. The risk of crystalline 
conversion of these samples will be much lower as FT-IR analysis demonstrated a 
secondary  interaction between NIF and PVPVA 64 polymer. With such an  
interaction, the polymer can slow down crystalline conversion and even more, it could 
possibly stabilize the supersaturated solution for a longer time period during 
dissolution. 
 
It has been shown that amorphous solid dispersion of nifedipine prepared with EPO 
with spray drying process yielded the highest intrinsic dissolution rates. This could be 
due to lack of hydrogen bond  interaction of the drug with the polymer which means 
that the water molecules in the dissolution media won’t  compete with the polymer to 
remove the amorphous drug molecule from the bulk. On the other hand, without 
polymer-drug interaction, the metastable amorphous nifedipine may convert easily to 
its stable crystalline form.  This is evident in the MDSC data presented as the melting 
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endotherm in 20 and 40% drug loads of NIF-EPO samples. Additionally, the low Tg, 
of  NIF-EPO solid dispersion systems may be unstable according to the well known 
Tg -50°C rule, declaring that the glass transition temperature of the solid dispersion 
should be above 50°C of the storage temperature to keep the system stable [28]. With 
the high molecular mobility environment, the high intrinsic dissolution rate may not 
translate to sustained supersaturated nifedipine solution but may result in fast 
precipitation of the reverted crystal nifedipine.    
 
Conclusion 
Amorphous solid dispersions of NIF with three polymers via HME, Rot and SD were 
made. The highest IDR was achieved when NIF-EPO sample was prepared by spray 
drying and second highest IDR with HME, with 40% drug loading. The reasons of the 
differences obtained were explained. However, these samples may not be the best 
candidates to proceed for formulation due to their unstable amorphous character. In 
that case, NIF-PVPVA 64 samples may be a better choice which the polymer has a 
better stabilizing ability compared to EPO polymer 
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. Table 1-I. Physicochemical properties of nifedipine (a), EPO, HPMCAS LF and PVPVA 64 (b) (MW, Tg, Tm ΔHfus are 
molecular weight, glass transition and melting point temperature, and heat of fusion, respectively) 
 
(a) MW (g/mol) 
Tg and Tm 
(°C) 
Aqueous 
solubility 
H-
bonding 
Charge pKa ΔHfus  
 
Nifedipine 346.335 
Tm 172.1 
 .6 μg/mL 
1 donor 7 
acceptors 
Neutral 3.93 106.4±3.63  
Tg 47±1  
         
(b) 
Polymer 
Polymer type 
Monomer 
MW 
(g/mol) 
MW 
(g/mol) 
Tg  (°C) 
Solubility 
H-
bonding 
Charge 
Aqueous 
Solubility 
in 
Methanol 
Eudragit E 
100 
Copolymer 399.522 135000 52 
1g of 
polymer 
dissolves in 
7g 
7 
acceptors 
Cationic ≤pH  .  
HPMCAS 
LF 
Homopolymer 286.28 18000 120 
Freely 
soluble 
9 
acceptors Anionic ≥pH  .  
6 donors 
PVP-
VA64 
Random 
copolymer 
197.23 
45000-
70000 
100 
Freely 
soluble 
3 
acceptors 
Non-ionic pH 5-7 
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Table 1-II. Melting and glass transition temperature and heat capacity measurement 
of nifedipine with EPO, HPMCAS LF and PVPVA 64 solid dispersions respectively, 
processed by HME, Rot and SD with drug loads ranging from 5 to 40% (w/w) 
 
Polymer 
Drug 
Load 
% 
(w/w) 
HME Rot SD 
Tg   C) Tm   C) 
ΔHfus 
(J/g) 
Tg   C) Tm   C) 
ΔHfus 
(J/g) 
Tg   C) Tm   C) 
ΔHfus 
(J/g) 
EPO 
5 
47.5 
±2.2 
  
52.6 
±0.5 
  
50.5 
±2.6 
  
10 
46.9 
±0.3 
  
52.6 
±0.1 
  
54.1 
±3.0 
  
20 
42.6 
±0.1 
147.4 
± 0.4 
2.4 ± 
0.2 
42.0 
±0.4 
147.7 
± 0.0 
2.8 ± 
0.3 
43.0 
±0.6 
  
40 
41.0 
±0.2 
160.5 
± 0.0 
20.2 
± 3.0 
42.6 
±0.0 
156.0 
± 0.0 
21.1 
± 1.8 
41.0 
±0.4 
160.2 
± 0.3 
20.3 
± 0.7 
HPMCAS 
LF  
5 
111.4 
±1.2 
  
113.4 
±0.8 
  
104.6 
±1.3 
  
10 
101.7 
±1.9 
  
105.8 
±1.0 
  
94.9 
±1.7 
  
20 
90.1 
±0.7 
  
92.2 
±0.1 
  
78.9 
±0.3 
  
40 
68.3 
±0.3 
165.6 
± 0.2 
5.2 ± 
0.5 
68.8 
±1.1 
163.6 
± 0.4 
12.4 
± 1.3 
65.3 
±1.4 
164.5 
± 0.1 
8.6 ± 
0.1 
PVPVA 
64 
5 
105.2 
±0.7 
  
106.4 
±0.4 
  
101.2 
±4.5 
  
10 
104.0 
±0.7 
  
103.9 
±0.8 
  
100.2 
±0.4 
  
20 
99.4 
±0.4 
  
98.9 
±0.1 
  
97.5 
±0.9 
  
40 
92.3 
±4.4 
  
88.9 
±0.2 
  
88.9 
±4.8 
  
40* 
 
  
125 
.57 
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Table 1-III. Intrinsic dissolution rates of nifedipine with EPO, HPMCAS LF and 
PVPVA 64 respectively processed by HME, Rot and SD with drug loads ranging from 
5 to 40% (w/w) 
 
 
Polymer 
Drug Load 
% (w/w) 
Intrinsic Dissolution Rate (mg/min/cm
2
) 
HME Rot SD 
EPO 
5 0.499 ± 0.026 0.147 ± 0.021 0.891 ± 0.095 
10 2.077 ± 0.279 0.191 ± 0.009 1.748 ± 0.14 
20 3.053 ± 0.017 0.223 ± 0.574 4.497 ± 0.574 
40 5.24 ± 0.995 0.0044 ± 0.0004 10.077 ± 0.442 
HPMCAS 
LF  
5 0.139 ± 0.096 0.295 ± 0.141 0.065 ± 0.021 
10 0.147 ±0.034 0.233 ± 0.091 0.109 ± 0.023 
20 0.418 ± 0.059 1.30 ± 0.227 0.221 ± 0.013 
40 0.452 ± 0.124 0.174 ± 0.057 0.478 ± 0.198 
PVPVA 64 
5 0.383 ± 0.045 0.552 ± 0.129 0.449 ± 0.031 
10 0.71 ± 0.276 0.856 ± 0.269 0.562 ± 0.161 
20 0.769 ± 0.164 0.588 ± 0.236 0.324 ± 0.086 
40 0.153 ± 0.094 0.293 ± 0.064 0.113 ± 0.015 
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Table 1-IV ANOVA analysis of the 3x3x4 factorial design of NIF samples with IDR 
as response 
 
Analysis of Variance for IDR, using Adjusted SS for Tests 
 
Source               DF    Seq SS   Adj SS   Adj MS       F      P 
Process               2    6.8496   6.8496   3.4248  237.66  0.000 
Polymer               2   23.6190  23.6190  11.8095  819.50  0.000 
DL                    3    8.7270   8.7270   2.9090  201.87  0.000 
Process*Polymer       4   19.7815  19.7815   4.9454  343.18  0.000 
Process*DL            6    7.6740   7.6740   1.2790   88.75  0.000 
Polymer*DL            6   19.0706  19.0706   3.1784  220.56  0.000 
Process*Polymer*DL   12   13.2428  13.2428   1.1036   76.58  0.000 
Error                72    1.0376   1.0376   0.0144 
Total               107  100.0021 
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Fig. 1-1. Chemical structures of nifedipine and the polymers used in the study (a)  
nifedipine, (b) EPO, (c) HPMCAS LF and (d) PVPVA 64. 
 
 
 
 
 
 
 
 
(b) 
(a) 
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Fig. 1-2 a and b FT-IR spectra of HME processed NIF-HPMCAS LF with 5% (a) and 
40% (b) drug loading 
 
 
 
 
 
(b) 
(a) 
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Fig. 1-3 a and b FT-IR spectra of HME processed NIF-PVPVA 64 with 5% (a) and 
40% (b) drug loading 
 
 
 
 
 
(b) 
(a) 
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Fig. 1-4. DSC thermogram of HME processed 40% DL of nifedipine-EPO  
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Fig.1-5. DSC thermogram of HME processed 40% NIF-HPMCAS LF 
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Fig.1-6. XRD diffractogram of HME processed NIF-EPO samples at 5, 10, 20 and 40 
% nifedipine concentrations  
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Fig. 1-7 XRD diffractions of HME processed NIF-HPMCAS LF samples with 5, 10, 
20 and 40 % drug concentrations 
 
 
 
 
 
 
 
 
 
 
 
 
 33 
 
 
 
 
Fig. 1-8. FT-IR spectra of Rot processed NIF-HPMCAS LF with 5% (a) and 40% (b) 
drug loadings  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(b) 
(a) 
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Fig. 1-9. FT-IR spectra of Rot processed NIF-PVPVA 64 with 5% (a) and 40% (b) 
drug loadings  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(a) 
(b) 
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Fig. 1-10. DSC thermogram of Rot processed 40% NIF-PVPVA 64 with a presence of 
two Tgs 
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Fig. 1- 11. XRD spectrograms of Rot processed NIF-PVPVA 64 at 5, 10, 20 and 40 % 
nifedipine concentrations  
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Fig. 1- 12. DSC thermogram of Rot processed 20% NIF-EPO with a presence of 
melting endotherm 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 38 
 
 
 
 
 
 
Fig. 1- 13. DSC thermogram of Rot processed 40% NIF-EPO with a presence of 
melting endotherm 
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Fig. 1- 14. XRD spectrograms of Rot processed NIF-EPO with 5, 10, 20 and 40 % 
drug concentrations 
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Fig. 1- 15. DSC thermogram of Rot processed 40% NIF-HPMCAS LF with a 
presence of melting endotherm 
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Fig. 1- 16. XRD spectrograms of Rot processed NIF-HPMCAS LF with 5, 10, 20 and 
40 % drug concentrations 
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Fig. 1- 17. DSC thermogram of SD processed 40% NIF-EPO with a presence of 
melting endotherm 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 43 
 
 
 
 
 
 
 
 
Fig. 1- 18. XRD of SD processed NIF-EPO with drug concentrations of 5, 10, 20 and 
40% 
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Fig. 1- 19. DSC thermogram of SD processed 40% NIF-HPMCAS LF with a presence 
of melting endotherm 
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Fig. 1- 20. XRD of SD processed NIF-EPO with drug concentrations of 5, 10, 20 and 
40 
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   Fig. 1- 21. Intrinsic dissolution rates of nifedipine comparing polymer and processing methods with drug concentrations 
5, 10, 20 and 40 %
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Fig. 1-22.  Interaction plots of process methods, polymer types and nifedipine 
concentration in the samples. 1, 2 and 3 are EPO, HPMCAS LF and PVPVA 64 
respectively and for process  1, 2 and 3 are HME, Rot and SD respectively 
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Abstract 
 
Flory-Huggins (F-H) interaction parameter is used to predict the miscibility of 
drug-polymer amorphous solid dispersions. Most commonly used method to 
determining the interaction parameter is by using the solubility parameters or by 
measuring the melting point depression of the two mixed components. Although 
these are very popular methods, they are not without limitations. For the solubility 
parameters, there is a problem with accurate calculations and with melting point 
depression, the temperature and composition of the system keeps changing even 
though the interaction parameter is dependent on these values. By annealing the 
drug-polymer mixture at a set temperature and by determining the equilibrium 
solubility of nifedipine in polymers, we have been able to improve on the 
determination of the F-H interaction parameters.  
 
Keywords: Flory-Huggins interaction parameter, melting point depression, 
solubility parameter, DSC, nifedipine, miscibility, polymer 
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1. Introduction 
 Most of the poorly water soluble drugs have crystalline structures.  Therefore 
they are challenging to prepare as pharmaceutical formulations due to the low 
solubility which leads to low bioavailability. In many cases for such a drug, this 
property can be the limiting factor minimizing the success of the product.  
There have been numerous techniques used to formulate such drugs by improving 
their solubility by manipulating the morphological and other physical-chemical 
properties. One such technique is to prepare an amorphous solid dispersion of a 
drug in a water soluble polymer. Compared to the crystalline state, a drug in an 
amorphous state has higher solubility in a solution due to the higher energy state 
which is the result of greater entropy and free energy [1]. However in the 
amorphous form, the drug is thermodynamically unstable for the same reason. 
Suitable polymers can modify crystallinity of the drug and degree of crystallization 
thus, improve the thermodynamic stability.  
 
The purpose of producing an amorphous solid dispersion of a drug in an 
amorphous polymer is to improve the bioavailability of the drug. In this way, high 
therapeutic concentrations can be incorporated into the formulation. In many 
cases, if therapeutic concentration is high, the supersaturation state is created. 
However in the supersaturated state, faster crystallization of the drug may occur 
during storage as the result of higher kinetic driving force (the molecular mobility 
of drug in the polymer matrix) and the thermodynamic instability of the 
amorphous drug.  
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In order to extend shelf-life, besides limiting drug concentration, polymers with 
high glass transition temperatures (Tgs) should be kept at much lower storage 
temperature (when temperature of storage is deducted from the glass transition 
temperature of the solid dispersion, the value obtained should be higher than  0  C) 
in order to minimize molecular mobility of the drug [1-5]. The drug which is 
transformed to an amorphous state by the interaction with the polymer must stay 
so during the shelf life of the product. Therefore knowing the degree of the 
miscibility of the polymer with the drug is very important.  
 
Flory-Huggins define this interaction parameter, χ, eq. ( ) 
                                  …………..( ) 
where ΔGmix is the change in Gibbs free energy, R is the gas constant and T is 
temperature, nd, p is the number of moles of drug and polymer respectively, ϕd,p is 
the volume fractions of the drug and the polymer respectively and χ is the 
interaction parameter. The first two terms of the equation is the entropy 
contribution of the system and the last term is the contribution from the change in 
enthalpy as the result of mixing in eq. (1). 
Flory-Huggins interaction parameter, χ, is defined as “ the thermodynamic 
interaction energy of a solvent and a solute” [6] and has been used as a predictive 
tool to determine the interaction between a drug and a polymer in the molten state. 
The calculated χ can tell whether the drug will be miscible with the polymer used 
where (χ<0). Very little or no interaction will produce a (χ>0) value. In a strong 
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interaction state between the drug and polymer, the amorphous mixture of the drug 
will remain stable much longer than if there was no interaction with the polymer. 
 
 
1.1 Solubility parameter for calculating χ 
The Flory-Huggins interaction parameter can be calculated using the solubility 
parameters of Hildebrand [6], by measuring melting point depression or with 
computational analysis of the drug and a polymer [6-13].  
 olubility parameters, δ, show similar values for similarly structured solvents and 
solutes which can be used to select a better solvent for a solute to make a solution. 
Solubility parameter can be used to predict the solubility of the solid drug in the 
polymer in the solid form. 
  olubility parameter, δ, is defined as the square root of cohesive energy density 
which is related to the change in the internal energy per volume of a substance eq. 
(2).  
   
    
 
 
   
……………………………………..………………………...... (2) 
The cohesive energy has been predicted by using structural group contributions of 
the compounds. The three groups that contribute to the cohesive energy are the 
dispersion forces, polar interaction and hydrogen bonding interaction which is 
represented in eq. 3. 
              ………………………………………….…………..(3) 
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Since the solubility parameter is the square root of the cohesive energy density, 
individual solubility parameter component can be represented in eq. (4) suggested 
by Hansen [15]. 
    
    
    
    
 …………………………………………………….…(4) 
By using the solubility parameters of a solvent and a solute, Hildebrand and Scott 
[16] developed an equation to calculate the Flory-Huggins interaction parameter 
shown in eq. (5). 
   
                  
 
  
 +0.34……………………………………..…( ) 
where χ is the interaction parameter, v is the volume of each lattice site, R is the 
gas constant and T is the absolute temperature.  The first term is the enthalpy 
contribution and 0.34 is the value for entropy. 
Flory-Huggins theory is based on the Gibbs free energy and it is used to determine 
the thermodynamic miscibility of a solute in a solvent system shown in eq. (6) 
                   ……………………………………………… (6) 
where entropy of mixing will usually be positive due to mixing of two components 
but depending on the sign of ΔHmix. The miscibility can be favored when ΔGmix is 
negative, where, the solute will readily solubilize in the solvent. They will not mix 
if ΔGmix is positive.  
Eq. (5) can be rewritten to determine the interaction parameter shown in eq. (1). 
In eq. (1), since the number of moles and volume fraction will always remain as 
positive values, the sign of the enthalpy term will be determined by the value of 
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the interaction parameter, χ. Therefore, calculating the Flory-Huggins interaction 
parameter can be useful to predicting the solubility of a component in a system. 
1.2. Calculations based on melting point depression 
Marsac et al. [7] have argued that sometimes specific hydrogen bonding between a 
drug and a polymer contributes to the miscibility which cannot be distinguished by 
the solubility parameter calculations. The changes occurred in the melting point of 
an insoluble drug and a polymer is specific for each polymer which can be 
measured by the melting point depressions. Starting from that finding the 
interaction parameter, χ, can be calculated. 
Melting point depression of a drug and polymer systems have been measured and 
studied by number of groups in hope to determine the Flory-Huggins interaction 
parameter [6,8,12]. Nishi and Wang [17] determined the melting point depression 
of a crystalline polymer (poly (vinylidene fluoride), PVF2) by melting it with an 
amorphous one (poly (methyl methacrylate), PMMA) at 10-80% (w/w) PVF2 to 
PMMA ratio. They explained that the depression of melting temperature of the 
crystalline polymer as the result of mixing of the crystalline polymer with the 
amorphous one which led to an energy reduction in the overall mixture. This was 
not the result of morphological effects such as particle size reduction etc. as 
speculated earlier. They have successfully calculated the interaction parameter for 
the crystalline and amorphous polymers. 
Therefore the melting point depression method was more specifically used to 
calculate the interaction parameter instead of using solubility parameter [7]. The 
idea is based on the two compounds’ melting point temperature to be specific to its 
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structure and thus mixing of the two should be predicted. The interaction 
parameter χ can be calculated by using the eq. (7): 
.….(7) 
where TM  is the melting point temperature of the drug in the mixture or in its pure 
state indicated by “mi ” and “pure” respectively, ΔHfus is the heat of fusion of a 
drug, m is the degree of polymerization and Φ is the volume fraction. 
This approach has been used quite frequently since it is a convenient and 
practicable because melting points can be easily determined by the differential 
scanning calorimeters. However, it must be mentioned that the interaction 
parameter, χ, is both temperature and concentration dependent which means that 
the value of χ can change with change in either temperature or concentration of the 
drug present in the polymer [6]. However, these are not taken into consideration 
with the melting point depression method where χ is calculated using a set of drug-
polymer mixtures with decreasing drug concentrations which alters the melting 
point temperature in return. To obtain the interaction parameter, χ, with one set of 
temperature and concentration, another approach has to be taken. 
 
1.3 Calculations based on heat of fusion 
In this study, heat of fusion of the undissolved drug in the polymer will be 
used to determine the equilibrium solubility. Using this value we can calculate the 
solubility of the drug in the polymer which will be used to calculate the actual 
volume fraction of the dissolved drug in the drug-polymer mixture. The Flory-
 
1
 𝑀
𝑚𝑖𝑥
 
1
 𝑀
𝑝𝑢𝑟𝑒   
  𝑓𝑢𝑠
  
 lnΦ𝑑𝑟𝑢𝑔   1  
1
𝑚
 Φ𝑝𝑜𝑙𝑦𝑚𝑒𝑟 =  Φ𝑝𝑜𝑙𝑦𝑚𝑒𝑟
2   
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Huggins interaction parameter, χ,  have been calculated for a drug-polymer system 
of nifedipine with three polymers: (Eudragit E 100, hydroxypropyl 
methylcellulose acetate succinate and poly (vinyl pyrrolidone vinyl acetate) by 
using the melting point depression approach with the actual volume fraction of 
drug in the mixture and one annealing temperature that is specific for one 
measurement at a time.  
The Flory-Huggins theory eq. (6) takes into account of the size differences 
between a small molecule (i.e. drug) and a larger molecule (i.e. polymer) by 
accepting that the segments of the polymer chain are in equal size as the smaller 
molecule (drug). Since then, research groups have taken this work and applied to 
crystalline drug and amorphous polymer systems to calculate the interaction 
parameters [6-12]. The idea is that when a crystalline drug is mixed in an 
amorphous polymer and they are miscible, the chemical potential of the drug will 
be smaller than the pure drug which will be shown through a depression in the 
melting point of the drug in the mixture. However, it must be noted again that the 
interaction parameter, χ, is dependent on drug concentration (melting of the drug at 
a specific volume fraction) and the melting temperature of each combination. With 
the melting point depression approaches these two are not constant throughout 
which can lead to overestimated value of χ than the actual one.  
In this paper, an amorphous solid dispersion of a drug and a polymer that are 
“miscible” means that the amorphous drug and amorphous polymer e ist as a one-
phase by a liquid-liquid mixing of the two components in the molten state [5]. 
2. Materials and Methods 
 57 
 
2.1. Materials 
Eudragit E-100, EPO (Methacrylate copolymer) was kindly provided by Evonik 
(Parsippany, NJ). Nifedipine was purchased from RIA International (East 
Hanover, NJ ), HPMCAS LF (hydroxypropyl methylcellulose acetate succinate) 
by Shin-Etsu Chemical Co., Ltd (Biddle Sawyer Corp, New York, NY) and 
PVPVA  64  (polyvinyl pyrrolidone co-vinyl acetate 64) by BASF (Florham Park, 
NJ) were purchased. Chemical structures and physical-chemical properties of the 
drug and polymers used are given in Figure 1-1 and in table 1. 
 
 
 
 
2.2. Methods 
 
2.2.1.  Solubility parameter calculations 
Solubility parameters of nifedipine and polymers were calculated using Eqs. (18) - 
(20).  
 
2.2.1.1. Sample preparation, annealing; characterization of the annealed samples; 
the measurement of heat of fusion and melting point temperature determination 
Physical mixtures of nifedipine and a selected polymer; EPO, HPMCAS LF and 
VA 64, respectively, in loads of 30 to 90% (w/w) were prepared in a mortar by 
mildly stirring the weighed amount of the drug and the polymers. The samples 
were packed into aluminum pans individually (5-7 mg each) and annealed at a set 
temperature (130,     and  6   C) in a muffle furnace for 18 hours. The annealing 
temperatures were chosen based on the drugs melting point (172-173 °C). We 
selected two temperatures (10 and 20 °C) below the melting point of the drug and 
another temperature based on the polymer with the highest glass transition 
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temperature was also selected and our third temperature was  0 °C above  the 
glass transition temperature ( 30  C). At this temperature, there is no chemical 
decomposition and the polymer will be flexible. 
 Following thermal annealing, each sample pan was quench-cooled and reheated at 
10 °C/ minute in a Differential Scanning Calorimeter (DSC) Q2000 (TA 
Instruments, New Castle, DE) to measure the change in heat capacity and the 
melting point of the sample. Heat of fusion (ΔHfus) of nifedipine obtained from the 
DSC measurement was used to calculate the weight fraction of the undissolved 
nifedipine in a gram of polymer. The weight fraction was used to estimate the 
volume fraction (φ) of dissolved nifedipine. By applying this value, the volume 
fractions used in the Flory-Huggins equation were corrected accordingly for χ 
calculation. The value of χ was also calculated from the observed melting point 
depression (ΔTm) data and estimated φ (from the total weight fraction in the 
formulation). The solubility parameters were determined based on eq. (3) and 
Hildebrand and  cott’s method eq. (4) was used to calculate the interaction 
parameter. 
2.2.1.2. Determination of χ by the use of melting point depression 
In an amorphous solid dispersion, mixing of a crystalline drug which has a high 
melting temperature with an amorphous polymer having some miscibility with the 
drug, will lower the melting temperature of the drug in a mixture containing 
increasing amounts of polymer furthermore. Their melting point temperature 
should be determined individually and placed in eq. (7).  
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2.2.1.3. Development of formula to determine nifedipine solubility with heat of 
fusion measurements  
In the annealing experiments of the physical mixtures of nifedipine and polymer, 
heats of fusion of undissolved nifedipine were measured as described in 2.2.1.1 the 
values measured were plotted against the drug weight fraction in each mixture to 
obtain standard curves for each set of nifedipine -polymer mixture. These were 
used to determine the solubility of nifedipine in each polymer and in estimation of 
the amount of nifedipine in a mixture with an unknown drug load.   
From the heat of fusion measurement we can determine the amount (weight) of 
undissolved nifedipine by the following mass balance eq. (8) 
[Wt. of undissolved drug] = [Total wt. of drug] – [Wt. of drug dissolved in 
polymer]....(8) 
If we divide eq.(8) with the total weight of the formulation, we can obtain the 
equation expressed in weight fraction eq.(9)  
𝑓   𝑓   𝑓 ……………………………………………………………….( ) 
where  fd  is the total weight fraction of nifedipine, fp is the weight fraction of the 
polymer and X is the solubility which is the amount of nifedipine in grams 
dissolved in one gram of polymer. 
Since the mixture consists of two components, by adding fd  and fp will equal unity 
(=1) in which case, eq. (9) will become eq. (10) 
𝑓   𝑓        ……………………………………………………... ( 0) 
It also represents       , the heat required to melt the undissolved nifedipine in a 
gram of formulation, which is determined by the DSC. Since eq. (3) involves 
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calculation of Δhm, which is the molar heat of fusion of nifedipine per gram of the 
drug, we can replace fd,μ  with      leading to eq. (11) 
    𝑓       ………………………………………..………………........(11) 
and rearranging eq. (11) and substituting it into eq. (10) it will yield eq. (12) 
    𝑓                ……………………………….…............(12)  
Once heat of fusions (    ) are obtained they can be plotted against weight 
fraction of nifedipine, having the slope      Δ     and the intercept of    Δ    
as shown in Figure 3 a, b and c. 
Once the solubility of nifedipine in a given polymer is determined, the interaction 
parameter, χ, can be further obtained by using eq. (15). 
      
 
     
                  
    …………………………(  ) 
The solubility parameters of the polymers and nifedipine were calculated using the 
Hoftyzer and Van Krevalen method and are reported in Table 2.  Each solubility 
parameter component can be calculated using the equations shown below: 
δd= 
V
Fdi
……………………………………………………………………( 6) 
δp=
V
Fpi 2
 ……………………………………………………………………( 7) 
δh=
V
Ehi
 ……………………………………………………………………(  ) 
In the aforementioned equation,  Fdi is molar attraction constant due to dispersion 
component, Fdi is molar attraction constant due to dispersion component and V is 
the molar volume of substance. 
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3. Results  
Once the solubility parameters were calculated, Flory-Huggins interaction 
parameters were calculated using eq. (4) and are reported in Table 2.  
The heat of fusion of undissolved nifedipine in each polymer mixture will change 
depending on the concentration of polymer in the mixture as well as the polymer 
used shown in Fig 2a-c. Plotting the change in heat of fusion of nifedipine (ΔHm) 
annealed at different temperatures at different weight fraction of nifedipine and 
polymer physical mixtures will yield slopes shown in Figure 2-2 a-c.  From the 
estimated solubility, the interaction parameters were calculated and are reported in 
Table 3. The only problem with determining the solubility of nifedipine came 
when the solubility value of nifedipine in E O annealed at  30  C which was 
negative because the nifedipine was not soluble in EPO after a certain increase in 
the polymer concentration at that temperature. Since the solubility value was 
negative, we could not calculate the interaction parameter. The standard curves 
obtained for nifedipine dispersed in EPO, HPMCAS LF and PVPVA 64 
respectively, seem to be all linear (R
2
= 0.9972, 0.9992 and 0.974 respectively in 
the given order); indicating that the solubility (X) of nifedipine can be determined 
from these graphs. The related equations are shown by eqs. (8)-(12). Accordingly, 
we obtained 6.7% solubility with nifedipine in EPO, 13.9% in PVPVA 64 and 
13.2% in HPMCAS LF with no further calculations. This rough estimates could be 
used in formulation developments since it is fast method for comparisons and 
evaluations. Nifedipine-EPO   EPO, which has the lower Tg ( 2  C) than the other 
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two polymers ( 00 and  20  C) seems to dissolve more drug. Therefore, at the 
annealing temperatures, EPO chains are much more flexible compared to the other 
two polymers which may lead to more mixing. The more miscible the drug is with 
the polymer, the slope tends to be smaller. 
If the hydrogen bonding was the dominant cause of the drug-polymer miscibility, 
as seen from Table1, HPMCAS LF should have been the best candidate for 
solubilizing the drug having 1 donor and 7 acceptor sites whereas EPO has only 7 
acceptors and PVPVA 64 has 3 acceptors. However, the Tg of values in Table 1 
show that HPMCAS LF has the highest Tg and this polymer property is 
dominating the miscibility of the drug-polymer mixture. 
As the annealing temperature increases, the interaction parameter, χ, obtained in 
the heat of fusion as well as melting point depression show a decreasing trend 
except for nifedipine-HPMCAS LF combination around     and  6   C, which 
could be explained by the insignificant differences created by small increase of 
temperature from     to  6   C. When these two are grouped and compared with 
the interaction parameter value calculated at  30  C, the same decreasing trend can 
be seen.  
The decreasing trend in the interaction parameter values can be explained by the 
increase in polymer mobility and flexibility at elevated temperatures.  
Following the annealing processes of drug polymer mixtures, melting points were 
measured and used to calculate the interaction parameter as well shown in Table 3 
under melting point depression. 
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4. Discussions  
The χ values calculated by each method, heat of fusion and melting point 
depression as well as from solubility parameters are shown in Table 2.3. As the 
annealing temperature increases, the interaction parameter calculated by the heat 
of fusion and melting point depression methods show a trend to decrease which 
should be the case with the polymer being more mobile and flexible ready to 
incorporate more drug molecules within themselves. The interaction parameters 
calculated from solubility parameters a different trend compared to those 
calculated from the other two methods. It has been suggested that solubility 
parameter calculation by itself maybe too limited to be used as a guide for 
predicting the miscibility of a drug in polymer [17, 20]. For example, the solubility 
parameter calculations may not be as accurate or specific to the state (crystalline 
vs. amorphous) of the compound as it should be and it could change with changes 
in the temperature of the system. Since the solubility parameter values used for the 
calculation were taken at a lower temperature than the annealing temperature, this 
discrepancy may be explained. Also it has been suggested that solubility parameter 
may change with the change in system’s temperature [ 7] and suggested earlier, it 
does not differentiate specific bonding interaction that could contribute to a stable 
mixture [21]. With this in mind, the results obtained using the solubility parameter 
calculations show a deviation from the interaction parameters calculated using the 
other two methods. In general, χ values calculated by melting point depression 
were lower than the χ calculated by heat of fusion method. This could be so, 
because the heat of fusion method takes into consideration only the dissolved 
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portion of the drug and only that particular amount is used to calculate the actual 
weight fraction. Melting point depression does not take into account the actual 
weight fraction of the dissolved drug which leads to a gross over estimation of 
solubilized drug in each drug-polymer system.  
The second problem with the use of melting point depression approach is that the 
temperatures used to calculate χ keep changing with the change in drug fraction in 
each system. Since χ is temperature dependent, it would be a better choice to use 
one temperature setting (i.e. the heat of fusion approach) than to use a range of 
temperatures.  
Since the melting point depression method calculates the interaction parameter 
from a slope where the change in temperature is plotted against the change in the 
fraction of the polymer, the χ obtained from the slope is neither from one 
temperature nor a single concentration. Therefore, the melting point depression 
method does not follow the assumption of the Flory-Huggins theory for interaction 
parameter calculations where it is temperature and concentration dependent. 
However, the heat of fusion method determined the solubility of nifedipine in the 
polymer and then determined the equilibrium solubility of the drug. The calculated 
amount of the dissolved nifedipine volume fraction was used to determine volume 
fraction of the polymer. Also, by annealing the mixtures of nifedipine and the 
polymer at a set temperature, the miscibility of the two were determined at one 
temperature setting which meant that the temperature and the concentration were 
kept constant for calculating the interaction parameter.  
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There are several assumptions that are made in this solubility estimation that need 
to be addressed. Firstly, during the annealing process, not all of the drug will melt 
because the melting point of the drug was not exceeded while annealing. The 
changes in the heat of fusion are the result of the change in the polymer 
concentration only. If the total mass of the drug were melted, we will not observe a 
heat of fusion. Secondly, the heat of fusion of nifedipine, per gram, remains the 
same without taking into account of the formation of other polymorphs. Thirdly, 
there is no surface effect added to the equation since the assumption is that the 
particles in the physical mixture are not small enough to cause melting point 
depression by giving off excess energy. Since the amount of drug in the physical 
mixture is at the higher end, it can be assumed that the residual undissolved drug 
left in the mixture, the particles are large enough to not contribute to providing 
excess energy. Lastly, the period of time which the physical mixture is being 
annealed is long enough for the drug to thoroughly mix with the polymer at the 
selected annealing temperature and thus the dissolved drug is homogeneously 
spread within the polymer. 
There was a trend that could be observed with using the heat of fusion method 
especially with the PVPVA 64 polymer where the increase in the annealing 
temperature resulted in a smaller interaction parameter, χ, value whereas the 
melting point depression method does not show that trend but does the opposite 
with increasing values. This shows that the melting point depression method is not 
sensitive to temperature change of the system.  
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5. Conclusions 
 
We have been able to show that by annealing a drug in a polymer before obtaining 
the melting point depression temperature of nifedipine in polymer systems and 
calculate the solubility of the drug in polymer, we can correct the overestimated 
volume fraction of the actual dissolved drug in the polymer. Also by using an 
annealing method, there is only one temperature value that was used throughout 
the experiment. These have been done in order to stay true to the obtaining the 
Flory-Huggins interaction parameter where the composition and temperature must 
stay constant. This is something research groups have not considered doing 
previously which we believe adds value to estimating a more accurate interaction 
parameter values. The solubility determination of nifedipine in polymer mixtures 
using the heat of fusion method have shown to give a crude estimation for 
selecting a polymer which can dissolve the highest amount of nifedipine. This can 
be used as a quick method of detection while selecting different polymers for 
amorphous drug-polymer mixtures.  
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Table 2-1. Physicochemical properties of (a) nifedipine, (b)the polymers used; Eudragit E 100, HPMCAS LF and PVPVA 64 
where Tg and Tm are the glass transition and melting point temperatures and ΔHfus is the heat of fusion of pure nifedipine  
 
 
(b) 
Polymer 
Polymer  
type 
Monomer 
Molecular 
Weight 
(g/mol) 
Mol. 
Weight 
(g/mol) 
Tg  
(°C) 
H-bonding Charge 
Eudragit E 
100 
Copolymer 399.52 135000 52 7 
acceptors 
Cationi
c 
HPMCAS 
LF 
Homopolymer  286.28 18000 120 9 
acceptors 
6 donors 
Anioni
c 
PVPVA64 Random 
copolymer 
197.23 45000-
70000 
100 3 
acceptors 
Non-
ionic 
 
(a) Molecular 
Weight 
(g/mol) 
Tg Tm (°C) H-bonding Charge ΔHfus 
Nifedipine 346.34 Tm 172.1 
Tg 47±1  
1 donor 7 
acceptors 
Neutral 
 
106.4±3.
63  
  
7
0
 
 
 
Table 2-2. Calculated solubility parameters of nifedipine and polymers 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
R group 
mono MW 
(g/mol) 
δi 
(J/cm
3
)
1/2 
vi 
(cm
3
/mol) 
δ  van 
Krevelen) 
Eudragit EPO (Methyl:Butyl=1:1)         
R=CH3 257.33 20.76 221.58   
R=C4H9 299.41 19.96 270.69 20.4 
HPMCAS   
  
  
R=H (C 12 H 20 O 10) 324.3 38.40 147.94   
R=CH3 (C 18 H 32 O 10) 408.4 20.95 293.74   
R=COCH3 (C 24 H 32 O 16) 576.5 23.20 378.94   
R=COCH2CH2COOH (C 36 H 44 O 
28) 924.7 28.14 499.18   
R=CH2CH(OH)CH3   (C 30 H 56 O 
16) 672.8 26.02 463.96   
R=CH2CH(OCOCH3)CH3  (C 42 H 68 
O 22) 925 20.96 694.96   
R=CH2CH(OCOCH2CH2COOH)CH3  
(C 54 H 80 O 34) 1273.2 24.49 815.2 26.0 
PVP VA64         
1-vinyl-2-pyrrolidone 111.1 25.96 82.28   
vinyl acetate 86.1 22.28 66.87 24.3 
Nifedipine 346.34     24.8 
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Table 2-3. Calculated χ interaction parameter by three different methods 
 
 
 
    
Flory-Huggins χ Parameter 
Solubility 
Parameter 
Calculated 
χ 
Physical 
Mixture  
Annealing 
Temp (K) 
Heat of 
Fusion 
Melting 
point 
depression 
 
Nifedipine-
EPO  
403.15 
      C) N/A 0.623 
2.165 
428.15 
      C) 1.46 -0.0055 
438.15 
      C) 1.34 -0.259 
Nifedipine-
HPMCAS 
LF  
403.15 
      C) 3.41 0.420 
0.166 
428.15 
      C) 1.26 0.315 
438.15 
      C) 2.12 0.386 
Nifedipine-
PVPVA 64 
403.15 
      C) 2.41 -1.391 
3.48 
428.15 
      C) 1.45 -1.313 
438.15 
      C) 1.39 -0.554 
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Figure 2-1 a-c Overlay plot of heat capacity measurements from DSC of 
nifedipine-polymer mixtures (EPO, HPMCAS LF and     A respectively) 
annealed at      C for 18 hours of various concentrations (a) 90 % (w/w) (b) 80 % 
(w/w) (c) 70% (w/w) (d) 60 % (w/w) and (e) 50 % (w/w). 
b 
c 
a 
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Figure. 2-2 a-c. Plot of change in heat of fusion against drug weight fraction for 
each nifedipine -polymer , EPO, HPMCAS LF and PVPVA 64, respectively 
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Abstract 
 
 Miscibility and solubility prediction studies of poorly water soluble drugs with 
amorphous water soluble polymer have been reported. However, these studies have 
some drawbacks to be used universally for any drug-polymer combinations. Specific 
drug-polymer interaction and temperature used in the experimental setting and 
temperature used in the prediction of the drug solubility are two of the most important 
factors that need to be considered.   
The solubility of nifedipine with amorphous polymers, Eudragit E  00 (E O, 
H MCA  LF and     A 64, in amorphous solid dispersions prepared by hot melt 
e trusion (HME), rotary evaporation (Rot) and spray drying (  ) processes, were 
predicted at room temperature (2   C). The prediction was carried out by using a 
thermodynamic model utilizing heat capacity measurements made with differential 
scanning calorimeter (DSC) and Flory-Huggins interaction parameter, χ. The model 
calculated the change in Gibbs free energy of the amorphous solid dispersions 
prepared at the range of nifedipine drug concentrations. By calculating the χ 
interaction parameter using the solubility parameters of nifedipine and polymers and 
measuring the changes in the amorphous solid dispersion of nifedipine from room 
temperature to its melting point temperature, we were able to estimate the solubility of 
nifedipine in the polymers at room temperature.  
 
Keywords: amorphous; solid dispersion; Flory-Huggins interaction parameter; Gibbs 
free energy; solubility parameter; DSC; HME; rotary evaporation; spray drying 
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Introduction 
With the use of modern high throughput screening (HTS) techniques and 
combinatorial chemistry in drug discovery, more compounds that are poorly soluble in 
water are entering the drug pipelines of pharmaceutical companies. To enhance the 
solubility of these poorly soluble drugs, solid dispersions, or amorphous molecular 
level dispersions in polymeric systems have been used as pharmaceutical dosage 
forms. By dispersing the drug molecularly in a polymer matrix, given that the 
interaction between the drug and the polymer is not too strong, the dissolution and/ or 
apparent solubility of the drug which will lead to greater absorption and bioavailability 
of the drug can be increased [1-8].  
There are two important criteria when preparing a solid dispersion of a drug in an 
amorphous polymer. Firstly; the drug must be molecularly miscible with the polymer. 
Secondly, the drug incorporated in the system should be accommodated by the 
polymer molecules to have an acceptable shelf life. In other words, it should stay as an 
amorphous solid dispersion and not crystallize out during the shelf life. The miscibility 
of a drug in a polymer is important because it affects the stabilization of the drug when 
it is dispersed in the polymer matrix. It also lowers the chemical potential (Δμ) of the 
drug as the result of mixing with the polymer [8].  
Drug concentration can also affect the stability of the drug in the system i.e. with high 
drug concentration, the solid dispersion becomes unstable. The equilibrium solubility 
of the crystalline drug will be much less than the solubility of amorphous drug. The 
amorphous drug will have an e perimentally determined “apparent” solubility and not 
an equilibrium solubility since the amorphous drug will be metastable.  
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There have been various approaches to understand the miscibility of a drug and a 
polymer in an amorphous solid dispersion [9-14]. These include measurement of the 
changes in the glass transition temperatures [9-11], determination of Flory-Huggins 
interaction parameter by using melting point depression method or solubility 
parameters [12-14], measuring the miscibility of a drug in a monomer or oligomer of 
the same polymer [14] or using a hot stage microscope to visibly determine miscibility 
of the melt [9].  However, there are limitations to the methods mentioned above such 
as: 
(1) Polymers used in these experiments tend to have high glass transition temperatures 
which reduce the molecular mobility in the solid dispersion. They will be highly 
viscous and may not be suitable to determine miscibility on a hot stage microscope. 
(2) Determining miscibility with the use of a liquid monomer or an oligomer will limit 
the types of polymers that can be used to determine miscibility. Also there are 
assumptions that can interfere with the accuracy of such monomers, i.e. the interaction 
of a drug with a monomer will be the same as the drug with the polymer which could 
be different from drug-oligomer  
(3) Melting point depression can only be measured where the drug and the polymer 
are in their liquid state. 
  
An amorphous solid dispersion may contain high drug concentrations if the drug is 
miscible with the polymer in that case the concentration of the drug incorporated to 
the amorphous polymer is much higher than the solubility of its crystalline state. If the 
drug concentration exceeds the miscibility of the drug in the polymer, there is danger 
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of recrystallization. Therefore, it is important to determine the solubility and the 
miscibility of the drug in the polymer of interest to estimate the drug concentration 
that can be incorporated into the polymer without jeopardizing high amounts of 
amorphous drug reverting to the crystalline state. 
 
 n this paper, the term “solubility” is referred to the solubility of a crystalline drug in a 
polymer as an amorphous molecular dispersion (solid form), where the chemical 
potential of the solid state of the drug is equal to its liquid state. “Miscibility” is 
referred to that amount of liquefied drug that can mix with a liquid polymer. Since the 
temperature at which this mixing occurs is much higher than the glass transition 
temperature at this condition, reaching equilibrium state is very difficult.  
 
The solubility of a drug in a solid dispersion can be expressed with the change in the 
chemical potential (Δµ) of its pure form.  f Δμ of the drug in the solid dispersion is 
lower than the Δμ of the pure drug, the drug present in the solid dispersion will 
dissolve fully and the final concentration of the drug will be its apparent solubility. 
The term “apparent solubility” refers to a metastable or supersaturated solution which 
may initially contain high concentration of the drug and over time reduced 
concentrations that are thermodynamically stable.  f Δμ of the solid dispersion is 
higher than that of the pure drug, then some of the drug dissolved as solid dispersion 
will revert back to the pure crystals in the polymer matrix and precipitate. The 
maximum amount of drug that can be loaded in a solid dispersion is, when μ of the 
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drug in the solid solution is equal to μ of the drug at a solid state [10]. This is the 
highest stable concentration of drug in a drug-polymer matrix that can be achieved.  
 
In addition to the methods determining miscibility of a crystalline drug with a polymer 
discussed, there are other methods that have been developed to estimate the drug-
polymer miscibility by using Flory-Huggins solution Theory [15], which were carried 
out by measuring melting point depression or solubility parameter [12-14].  The 
calculation of χ according to solubility parameter and melting point depression were 
already explained in the previous paper [16]. However, these authors have explained 
the solid-solid solubility by using data obtained when both components were in the 
liquid state.  
 
For predicting amorphous solubility of a drug in a solid polymer, a temperature that is 
close to the room temperature (2   C) should be used to mimic the real-life conditions. 
 ot all methods used utilize this temperature.  n such cases, solubility parameter (δ) 
can be used. The only problem in its use is that; it does not take into account the 
specific secondary bondings in the calculations. To incorporate information of these 
bondings is important since they increase miscibility of a drug with a polymer.  
 
Another predictive method published recently, proposed a thermodynamic model to 
calculate the miscibility of a drug at room temperature [8]. These authors analyzed 
changes involved in the Gibbs free energy of solid dispersions (ΔGSS) as the result of 
formation of the amorphous solid dispersion by calculating the contributions of three 
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components (ΔG1, ΔG2 and ΔG3). The heat capacities of pure drug, pure polymer and 
the solid dispersions prepared are measured with differential scanning calorimeter 
(DSC) and the values were used to calculate ΔG1: 
      𝑓     𝑓          𝑑     
𝑓     𝑓         
 
 𝑑 
  
 
   
 
       
where ΔG1 is one of the component of the total change in the Gibbs free energy, CP is 
heat capacity, T is initial temperature and TM is the drug melting temperature, f 
denotes the weight fraction,1, 2 and 12 denote the drug, polymer and the mixture, 
respectively in Eq. 1.  
ΔG2 is calculated by measuring ΔhM, which is the molar enthalpy of melting of the 
pure drug, via DSC and replacing the value obtained in Eq. 2. 
             
 
   
                               
where ΔG2 is the second component of ΔGSS and n is the number of moles per gram of 
formulation in Eq. 2. ΔG3 is obtained purely by calculation using Flory-Huggins 
solution theory in Eq. 3. 
                                                   
where R is gas constant, ϕ is volume fraction and χ(T) is Flory-Huggins interaction 
parameter at temperature T. ΔGSS is calculated by using Eq. 4. 
                                             
ΔGSS is the combination of the total components of ΔG 1-3 where ΔGSS is the total 
change of Gibbs free energy of the solid dispersion and by using ΔGSS value obtained, 
we can determine Δµ. 
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where P is pressure. 
 The plot of change in Gibbs free energy versus drug concentration while normalizing 
each by the weight of polymer in the formulation, we will be able to obtain the slope 
shown in Eq. 5. Since we have different drug and polymer weight fractions for each 
formulation, ΔGSS should be calculated per gram of formulation. By plotting the right 
hand side of Eq. 6 against the drug weight fraction, the slope can be determined. 
    
  
  
    
 
𝑓 
                                  
 
ΔG*SS is the change in Gibbs free energy per gram of formulation and f denotes the 
weight fraction.  
The change in the Gibbs free energy of the solid dispersion can be related to the 
chemical potential of the drug in the solid dispersion. The drug concentration where 
supersaturation of the drug may occur (Δµ1,SS > 0) can be determined from the slope of 
ΔGSS that is plotted against drug fraction in the solid dispersion. The drug 
concentration where separation occurs will have a positive slope. 
Flory-Huggins interaction parameter, χ, can be determined using solubility parameter, 
δ, of a drug and a polymer as shown in Eq.7 which is based on Hansen’s idea to 
correlate solubility to cohesive energy [17]. The solubility parameter can be calculated 
by using the method developed by van Krevelen and Hoftyzer as shown in Eq. 7 [18]. 
  
        
 
  
                                  
where V is molar volume per structure unit  
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where δ is the solubility parameter and d, p and h represents dispersion, polar and 
hydrogen bonding, respectively. Solubility parameter components δd, δp and δh can be 
calculated as shown in Eqs. 9-11. 
   
    
 
                                     
where F is the group contribution from dispersion  
   
     
 
 
                                   
    
    
 
                                   
where E is the molar cohesive energy.  
 n this paper Bellantone et al.’s solubility estimations will be used for the solid 
dispersions obtained with three different methods, hot melt extrusion (HME), rotary 
evaporation (Rot) and spray drying (SD) and polymers used for the preparations were, 
EPO, HPMCAS LF and PVPVA 64. Heat capacities of the prepared samples were 
measured for further calculations. We have also used three different methods of 
calculating Flory-Huggins interaction parameter, χ, as previously reported to compare 
the resulting ΔG3 values. 
 
 
Materials 
The API (Active pharmaceutical ingredient) used in this study was nifedipine (NIF) 
which was purchased from RIA International (East Hanover, NJ). Eudragit E-100 
(EPO) was kindly provided by Evonik (Parsippany, NJ), HPMCAS LF by Shin-Etsu 
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Chemical Co., Ltd (Biddle Sawyer Corp, New York, NY) and PVPVA 64 was 
purchased from BASF (Florham Park, NJ) 
Methylene chloride was used as the solvent in both spray drying process and rotary 
evaporation process except for processing NIF (with HPMCAS LF in which case 
methanol was used). Both solvents were purchased from Sigma-Aldrich Co. (St. 
Louis, MO). 
 
 
Methods 
1. Hot melt extrusion (HME) 
Physical mixtures of NIF and EPO were prepared using a mortar and pestle with drug 
loadings of 5, 10, 20 and 40 % w/w. The mixture was then extruded using Haake 
Minilab micro compounder (Thermo Scientific, Waltham, MA). The extruded material 
was ground and sized through a # 40 sieve. The physical mixture went into the 
extruder through the funnel on the left hand side and softened with the temperature 
applied and extrudes out from the flush hole. The extrusion screw speed was set to 50 
RPM throughout the experiments and no shear force was additionally applied to the 
mixture. 
 
2. Rotary evaporation (Rot) 
 The same physical mixtures prepared for HME were used for rotary evaporation. 5-10 
grams of the physical mixture was dissolved in 50-100 mL of methylene chloride, 
with HPMCAS LF methanol had to be used as solvent, and the solvent was removed 
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by using a rotary evaporator apparatus Büchi Rotavapor from Buchi (New Castle, 
DE). The samples were collected by removing the foamy film created on inside of the 
flask with a metal spatula and ground by using a mortar and pestle. The particles were 
sized through a # 40 sieve.  
 
3. Spray drying (SD) 
Mini Spray Dryer B-290 (Büchi, New Castle, DE) attached to Inert Loop B-295 
cooling block was used in the spray drying experiment to manufacture amorphous 
solid dispersion of nifedipine with three different polymers. A solution of NIF and 
polymer was made using either methylene chloride or methanol (in the case when 
HPMCAS LF was chosen as the polymer matrix) with drug loads ranging from 5-40% 
w/w and the solid content of 3-5% w/w.  
All the collected materials were transferred into amber colored vials and were kept in 
a desiccator until further analysis was required 
 
Modulated Differential Scanning Calorimetry MDSC 
NIF-polymer samples were thermally analyzed with a MDSC instrument Q2000 (TA 
Instruments, New Castle, DE).  Samples were weighed (6- 8 mg) and placed in to 
aluminum pans with lids. Heating was controlled throughout the measurement and the 
samples were heated from room temperature up to 20- 30°C above the melting point 
of the pure drug at a rate of 5°C/ minute unless noted otherwise.  
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True Density Measurements of Polymers 
E O, H MCA -LF and     A 64 polymers were dried in a vacuum oven for 72 
hours at 40  C. The true density was measured using AccuPyc 1340 (Micrometrics, 
Norcross, GA) and Helium gas used as the analyzer gas with 10 repeated cycles. The 
true density measurements were used to determine the theoretical change in glass 
transition temperatures using Gordon-Taylor equation of solid dispersions and 
compare them to experimentally determined glass transition temperatures. 
PXRD 
PXRD was performed using X-Ray Diffraction Bruker D8 PXRD (Bruker AXS, WI). 
The samples were analyzed using Cu K α radiation to determine the crystalline or 
amorphous phases of the drugs. The X-Ray pattern was collected in the angular range 
of   < 2θ < 40° in the step scan mode (step width 0.02°, scan rate 1°/ per minute) 
Estimation of the stable drug load in a polymer mixture 
The estimation for the most stable drug loads were calculated using Bellantone’s 
method described in [8]. The Flory-Huggins interaction parameter were determined 
using heat of fusion method which was previously reported, melting point depression 
method and with the use of solubility parameters. 
Results and Discussions 
The Flory-Huggins interaction parameter, χ, obtained for each polymer was calculated 
using Eq. 6 and the results are shown in Table I. From the interaction parameter 
obtained with     A 64, it is observed that the product has the lowest χ therefore it 
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will show the highest miscibility. PVPVA 64 will be the most likely candidate to form 
a stable amorphous solid dispersion with nifedipine. 
The changes in total Gibbs free energy against nifedipine weight fractions were 
calculated and plotted in Figs. 3- 1 a-c. There are three components that make up the 
total change in the free energy which includes ΔG1 and ΔG2 that are calculated from 
the   C data using Eqs.   and 2 and ΔG3 which is calculated by using Flory-Huggins 
theory and can be determined by Eq. 3.  In Figs. 3-1 a-c, the ΔG1, ΔG2 and ΔG3 
components of ΔGSS were calculated according to solubility parameter, melting point 
depression and heat of fusion methods [16]. ΔG1 and ΔG2 were found the same in but 
ΔG3 differs in each application. However, the slopes the changes appear to be very 
small meaning that they are not sensitive enough to detect the stable concentration. In 
the total change in Gibbs free energy of nifedipine-EPO solid dispersions processed by 
HME, shown in Fig. 3- 2, no clear deflection point is observed. On the other hand, 
both Rot and SD processed nifedipine-EPO have minima at 10-15 % nifedipine 
concentration as seen in Figs. 3- 3 and 4. This may suggest that the use of HME for 
the nifedipine-EPO mixtures may not provide sufficient mixing to form a stable solid 
dispersion. Both Rot and SD were efficient for more effective mixing.  
Using HME method, nifedipine-HPMCAS LF solid dispersions showed similar results 
to EPO, having no minimum concentration seen in the ΔGSS vs. weight fraction of 
nifedipine curve in Fig. 3- 5.  
For Rot and SD processed solid dispersions the predicted concentrations were 10 and 
15 % as seen in Figs. 3- 6 and 7. This could be due to the high viscosity of the 
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polymer during the HME processing which may interfere with mixing of the drug with 
the polymer well. The use of solvent could improve this drawback. 
Using this prediction model, Nifedipine-PVPVA 64 solid dispersions appear to be the 
best candidates for forming stable amorphous solid dispersions. The solid dispersions 
prepared with this polymer show clearly identified minima in the plots drawn, Figs. 3- 
8-10. For plots obtained as in Fig. 3- 10 the lowest concentration (15 % in this case) is 
taken to be on the safe side. 
In Fig. 3-   , the processing effects on the ΔGSS for each method used to prepare 
nifedipine-PVPVA 64 amorphous solid dispersions are presented. With the HME 
method, the predicted drug concentration is 5 % which is much lower than that of the 
Rot or SD methods. This may indicate that HME method used is not effective in 
incorporating higher concentration of the drug compared to the other two methods. SD 
provided drug concentration of 15 %, shown in Fig. 3- 11 that can be accepted as the 
concentration that can be used to maintain amorphous character of the solid 
dispersion. Although some ΔGSS observed in SD which pointed out 10-30 % drug 
concentration could be incorporated, for safe incorporation in such cases it is advisable 
to use the lower concentration that provides the same ΔG reduction [8]. 
As it was indicated earlier, ΔG3s calculated with each polymer used were different 
with the use of Flory-Huggins interaction parameter, χ, calculated using three different 
methods. They are presented on Table 3-II a-c for each method. For all of the methods 
used, ΔG3 change with increasing drug concentration is similar and the overall trend 
does not change. This finding indicates that mixing of nifedipine with polymers, ΔG3, 
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is not the most important factor to determine the solubility of nifedipine in the 
polymers used as it has been suggested by Pajula et al. [12] and Marsac et al. [14]. 
Changes in the enthalpy and entropy of a crystalline drug to an amorphous solid 
dispersion may be the result of different bond modes or another translational change 
for the stabilization of the amorphous solid dispersions. 
 
There are some evidence of phase separation occurring in the higher drug 
concentration with some of the nifedipine-polymer combinations. In Figs 3-3, 3-4, 3-8 
and 3-9 which show the prediction models of solid dispersions prepared by Rot and 
SD for NIF-EPO and HME and Rot for NIF-PVPVA 64, there were sudden change in 
the slopes of ΔG/w2 vs. drug weight fraction plots which could be the indication of 
existence of two separate phases [18]. At the concentration region above 20 %, 
amorphous nifedipine may be coexisting with crystalline nifedipine. This was 
confirmed with XRD analysis for 40% drug concentration of Rot processed NIF-EPO 
sample but not for the other samples. With the use of DSC, melting endotherms were 
present for 20 and 40 % Rot and SD processed NIF-EPO samples but none was 
present in the NIF-PVPVA 64 samples. Therefore, it is possible that phase separation 
of nifedipine and EPO can occur. However, NIF-PVPVA 64 solid dispersions may 
require further testing to confirm the existence of the two phases. Since these 
predictions are made for determining suitable drug concentration that will remain 
stable over the period of pharmaceutical products’ shelf life, we need to select the drug 
concentration where there is only one, amorphous, phase present. 
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Conclusions 
By applying Bellantone et al. prediction equations, SD samples of nifedipine-PVPVA 
64 polymer at 15-30 % nifedipine concentrations were predicted to be the most stable 
solid dispersions which agreed with the Flory-Huggins interaction parameter 
calculation to be the most miscible drug-polymer combinations between the three 
polymers tested.  
Data obtained can be treated in an hour time when all the equations are fed into a 
spreadsheet for plotting the change in the Gibbs free energy. 
ΔG3 component which was accepted as the main variable in the former to be a small 
contributor compared to ΔG1 solubility estimations, was found that its contribution 
was small compared to ΔG1.  
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Table 3-I. Flory-Huggins interaction parameter, χ, for nifedipine and each polymer 
combination were calculated using Eq.6 and the solubility parameter, δ, calculated 
with van Krevelen’s method Eqs. 7-10 at 25 ºC. 
Calculated           χ                                C 
  EPO HPMCAS LF PVPVA 64 
Nifedipine 2.165 0.166 0.027 
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Table 3-II a. Change in Gibbs free energy, ΔG3, contributed from mixing of 
nifedipine with EPO polymer 
 
Drug load % 
(w/w) 
∆G3 J/g 
 (Heat of Fusion) 
∆G3 J/g  
(Melting Pt. Depression) 
∆G3 J/g   
(Sol. Parameter) 
40 -2.67 -8.66 0.21 
20 -2.33 -4.86 -1.08 
10 -1.62 -2.80 -1.06 
5 -1.05 -1.61 -1.02 
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Table 3-II b. Change in Gibbs free energy, ΔG3, contributed from mixing of 
nifedipine with HPMCAS LF polymer 
 
Drug load % 
(w/w) 
∆G3 J/g 
 (Heat of Fusion) 
∆G3 J/g  
(Melting Pt. Depression) 
∆G3 J/g  
 (Sol. Parameter) 
40 -1.17 -4.19 -4.67 
20 -1.37 -2.83 -3.06 
10 -1.11 -1.82 -1.93 
5 -0.78 -1.13 -1.19 
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Table 3-II c. Change in Gibbs free energy, ΔG3, contributed from mixing of 
nifedipine with PVPVA 64 polymer 
 
Drug load % 
(w/w) 
∆G3 J/g 
 (Heat of Fusion) 
∆G3 J/g  
(Melting Pt. Depression) 
∆G3 J/g  
 (Sol. Parameter) 
40 -1.21 -11.15 6.10 
30 -1.39 -8.01 3.47 
20 -1.52 -6.02 1.79 
15 -1.34 -4.46 0.95 
10 -1.21 -3.36 0.37 
5 -0.84 -1.89 -0.06 
1 -0.28 -0.49 -0.13 
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Fig. 3-1 a-c. Calculated changes in the total Gibbs free energy of amorphous solid 
dispersions of nifedipine-EPO solid dispersions were prepared by hot melt 
e trusion with drug concentrations  ,  0, 20 and 40% w/w. (c) ΔG3 was calculated 
with Flory-Huggins interaction parameter, χ, by using the (a) solubility parameter, 
(b) heat of fusion calculation and (c) melting point depression method   
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Fig. 3-2. Overall change in Gibbs free energy of amorphous solid dispersions of 
nifedipine with EPO prepared by hot melt extrusion with drug concentrations 5, 10, 20 
and 40% w/w. 
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Fig. 3-3. Calculated changes in total Gibbs free energy of amorphous solid dispersions 
of nifedipine with EPO prepared by rotary evaporation with drug concentrations 5, 10, 
20 and 40% w/w 
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Fig. 3-4. Calculated changes in total Gibbs free energy of amorphous solid dispersions 
of nifedipine with EPO prepared by Spray drying with drug concentrations 5, 10, 20 
and 40% w/w 
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Fig. 3-5. Calculated changes in total Gibbs free energy amorphous solid dispersions of 
nifedipine with HPMCAS LF prepared by hot melt extrusion with drug concentrations 
5, 10, 20 and 40% w/w 
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Fig. 3-6. Calculated changes in total Gibbs free energy of amorphous solid dispersions 
of nifedipine with HPMCAS LF prepared by rotary evaporation with drug 
concentrations 5, 10, 20 and 40% w/w 
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Fig. 3-7. Calculated changes in total Gibbs free energy of amorphous solid dispersions 
of nifedipine with HPMCAS LF prepared by spray drying with drug concentrations 5, 
10, 20 and 40% w/w 
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Fig 3-8. Calculated changes in total Gibbs free energy of amorphous solid dispersions 
of nifedipine with PVPVA 64 prepared by hot melt extrusion with drug concentrations 
5, 10, 20 and 40% w/w 
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Fig 3-9. Calculated changes in total Gibbs free energy of amorphous solid dispersions 
of nifedipine with PVPVA 64 prepared by rotary evaporation with drug concentrations 
5, 10, 20 and 40% w/w 
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Fig 3-10. Calculated changes in total Gibbs free energy of nifedipine-polymer 
amorphous solid dispersions of nifedipine with PVPVA 64 prepared by spray drying 
with drug concentrations 5, 10, 20 and 40% w/w 
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Fig 3-11. Comparison of processing methods (HME, Rot and SD) and the resulting 
change in Gibbs free energy of nifedipine-PVPVA 64 solid dispersions 
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APPENDIX I 
 
 
 
 
 
 
 
Fig. IA-1. A schematic diagram of a bench top conical twin-screw extruder. 
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Fig. IA-2. Diagram of spray dryer 
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Fig. IA-3 A schematic drawing of an intrinsic dissolution apparatus setup  
 
